Published in Blood on August 28, 2008
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Down syndrome--recent progress and future prospects. Hum Mol Genet (2009) 1.85
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood (2009) 1.84
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet (2013) 1.31
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest (2012) 1.29
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood (2009) 1.22
The aurora kinases in cell cycle and leukemia. Oncogene (2014) 1.20
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med (2012) 1.16
Malignancy in children with trisomy 21. Oncologist (2009) 1.12
JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol (2009) 1.10
High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One (2012) 1.08
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia (2013) 1.05
Myeloid leukemia in Down syndrome. Crit Rev Oncog (2011) 0.99
Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J (2011) 0.95
IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett (2010) 0.95
JAK Kinases in Health and Disease: An Update. Open Rheumatol J (2012) 0.94
Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood (2012) 0.93
AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia (2013) 0.87
NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Mol Cancer (2010) 0.86
MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol (2009) 0.85
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood (2013) 0.84
Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia. Clin Cancer Res (2013) 0.84
The biology of pediatric acute megakaryoblastic leukemia. Blood (2015) 0.84
DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia (2016) 0.83
His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. J Biol Chem (2015) 0.83
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica (2010) 0.81
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget (2016) 0.80
The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control. Cell Mol Life Sci (2015) 0.78
Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. J Hematol Oncol (2013) 0.77
Early lineage priming by trisomy of erg leads to myeloproliferation in a down syndrome model. PLoS Genet (2015) 0.76
Functional analysis of the NUP98-CCDC28A fusion protein. Haematologica (2011) 0.76
Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain. Neural Plast (2016) 0.76
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. Front Endocrinol (Lausanne) (2017) 0.75
Myeloid Proliferations Associated with Down Syndrome. J Hematop (2014) 0.75
Familial Myelodysplastic/Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. Front Oncol (2017) 0.75
Mouse models of diseases of megakaryocyte and platelet homeostasis. Mamm Genome (2011) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 8.59
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood (2005) 3.09
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 2.72
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood (2009) 2.58
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging (2014) 2.51
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol (2011) 2.50
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 2.46
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 2.39
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol (2008) 2.37
Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med (2005) 2.21
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development (2002) 2.16
Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A (2003) 2.16
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol (2003) 2.15
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica (2006) 2.09
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A (2006) 2.08
A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood (2009) 2.08
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol (2014) 2.07
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev (2010) 2.05
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood (2011) 1.99
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest (2010) 1.97
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol (2013) 1.97
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood (2009) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med (2012) 1.93
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (2006) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood (2007) 1.83
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol (2006) 1.82
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol (2011) 1.80
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene (2004) 1.79
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood (2008) 1.77
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol (2004) 1.76
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem (2005) 1.74
Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood (2010) 1.73
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica (2010) 1.71
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood (2006) 1.71
MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood (2009) 1.70
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood (2008) 1.69
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer (2007) 1.69
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood (2007) 1.66
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
SPRED1 disorder and predisposition to leukemia in children. Blood (2009) 1.65